DANIEL TOUSSAINT: Open Payments
NPI 1770113011 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$886 in 32 payments from 10 companies in 2025. Trend: 2023 $510 · 2024 $993 · 2025 $886
Food & beverage: $886
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 6 | $206 |
| Novo Nordisk Inc | 6 | $187 |
| GlaxoSmithKline, LLC. | 4 | $166 |
| PFIZER INC. | 6 | $150 |
| Amgen Inc. | 4 | $59 |
| Merck Sharp & Dohme LLC | 2 | $44 |
| Dynavax Technologies Corporation | 1 | $22 |
| IBSA Pharma Inc. | 1 | $20 |
| Exact Sciences Corporation | 1 | $15 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
Products named: Ozempic, AREXVY, ZEPBOUND, NURTEC ODT, MOUNJARO, SHINGRIX, OTEZLA, PREVNAR 20.
Industry payments across TX — which companies pay providers there.
